Company Profile

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâ€™s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

24-07-02	Akili, Inc., Virtual Therapeutics Corporation and Alpha Merger Sub, Inc Announce Management Changes	CI
24-07-01	Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index	CI
24-07-01	Virtual Therapeutics Corp. completed the acquisition of Akili, Inc. from SC Master Holdings, LLC, SC Pipe Holdings LLC, Chamath Palihapitiya and others.	CI
24-07-01	Akili, Inc.(NasdaqCM:AKLI) dropped from S&P TMI Index	CI
24-06-18	Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment	MT
24-06-18	Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game	CI
24-06-18	Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment	DJ
24-05-29	PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company	MT
24-05-28	Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million.	CI
24-05-14	Akili, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-14	Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M	MT
24-04-30	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
24-04-30	Akili, Inc. to Reduce Workforce	CI

23-01-25	Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating	MT
22-12-28	Morgan Stanley Initiates Akili at Equalweight, $2 Price Target, Cites Uncertainties Regarding EndeavorRx's Launch	MT
22-12-28	Morgan Stanley Initiates Akili at Equalweight With $2 Price Target	MT
22-11-18	BofA Securities Starts Akili at Neutral With $2 Price Target	MT
22-10-25	Credit Suisse Starts Akili at Outperform With $5 Price Target	MT

24-08-15	Aura Appoints Dr. Scott Kollins Chief Medical Officer	AQ
24-06-18	Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game	BU
24-05-29	Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company	BU
24-05-14	Akili Reports First Quarter 2024 Financial Results and Provides Business Update	BU
24-04-30	Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	BU

Manager	Title	Age	Since
Daniel Elenbaas PSD	President	-	2024-07-01
Scott H. Kollins CTO	Chief Tech/Sci/R&D Officer	-	2022-11-30
Cathy Reid SAM	Sales & Marketing	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-07-01	Adam Gazzaley	Tender	Founder	1,089,314	1.3837%
24-07-01	W. Martucci	Tender	Chief Executive Officer	148,238	0.1883%
24-07-01	Matthew Franklin	Tender	Chief Executive Officer	40,657	0.0516%

Akili, Inc. Stock

Stocks

AKLI

US00974B1070

Advanced Medical Equipment & Technology

Latest news : Akili, Inc.

Analysts' recommendations: Akili, Inc.

Press Releases: Akili, Inc.

Quotes and Performance

Managers and Directors: Akili, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKILI, INC.	-0.62%	-0.62%	-	-	34.01M
THERMO FISHER SCIENTIFIC, INC.	+0.45%	+0.69%	+22.36%	+1.97%	196B
INTUITIVE SURGICAL, INC.	-1.16%	-4.51%	-22.67%	+19.55%	144B
DANAHER CORPORATION	+1.57%	+0.57%	-3.14%	-15.11%	141B
BOSTON SCIENTIFIC CORPORATION	-0.49%	-0.82%	-56.89%	-15.05%	66.54B
EDWARDS LIFESCIENCES CORPORATION	+0.96%	-2.29%	+17.02%	+0.62%	53.09B
SIEMENS HEALTHINEERS AG	+0.61%	-1.09%	-27.71%	-30.42%	44.12B
AGILENT TECHNOLOGIES, INC.	+0.52%	+2.75%	+8.15%	+13.46%	37.93B
WATERS CORPORATION	-0.19%	-0.75%	+6.55%	+42.23%	36.96B
RESMED, INC.	-2.20%	-2.75%	-21.00%	-5.88%	29.41B
Average	+0.35%	-1.00%	-8.59%	+1.26%	83.21B
Weighted average by Cap.	+0.74%	-1.02%	-4.67%	+0.88%